AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
11 Sep 2019
Small Cap Feast
SigmaRoc Plc (SRC:LON), 64.5 | Science In Sport Plc (SIS:LON), 42.0 | 88 Energy Limited (88E:LON), 0.6 | Charles Taylor (CTR:LON), 0 | ECO Animal Health Group plc (EAH:LON), 248 | Armadale Capital Plc (ACP:LON), 4.5 | KRM22 Plc (KRM:LON), 39.5 | Conroy Gold & Natural Resources Plc (CGNR:LON), 31.3 | AltynGold Plc (ALTN:LON), 109
-
-
-
Derren Nathan
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Small Cap Feast
SigmaRoc Plc (SRC:LON), 64.5 | Science In Sport Plc (SIS:LON), 42.0 | 88 Energy Limited (88E:LON), 0.6 | Charles Taylor (CTR:LON), 0 | ECO Animal Health Group plc (EAH:LON), 248 | Armadale Capital Plc (ACP:LON), 4.5 | KRM22 Plc (KRM:LON), 39.5 | Conroy Gold & Natural Resources Plc (CGNR:LON), 31.3 | AltynGold Plc (ALTN:LON), 109
- Published:
11 Sep 2019 -
Author:
Derren Nathan - Pages:
-
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019